A Phase 1/2 interventional study of PRAX-222 - Initial Dose and PRAX-222 - Initial Ascending Doses in SCN2A-DEE and Epilepsy, sponsored by Praxis Precision Medicines. Active, not recruiting at 3 sites in 2 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-08-03.
Sponsored by Praxis Precision Medicines · Phase 1/2, Interventional, and Treatment
The goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy (DEE), aged 2 to 18 years.
1,805 studies on the registry are indexed under Epilepsy; 417 are open to participants now.
This study's planned enrollment of 60 is above the median of 50 across 1,206 interventional studies indexed under Epilepsy.
Browse Epilepsy studies →Praxis Precision Medicines is the lead sponsor of 17 studies on the registry; 4 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Open-label PRAX-222
Drug: PRAX-222 - Initial Dose
Initial dose escalation consisting of double-blind ascending doses of PRAX-222
Drug: PRAX-222 - Initial Ascending Doses
Double-blind placebo procedure
Procedure: Placebo
Optional dose escalation consisting of double-blind ascending doses of PRAX-222
Drug: PRAX-222 - Optional Ascending Doses
Double-blind placebo procedure
Procedure: Placebo
Double-blind fixed-dose PRAX-222
Drug: PRAX-222 - Fixed Doses
Double-blind placebo procedure
Procedure: Placebo
Open-label PRAX-222
Drug: PRAX-222 - Fixed Doses
PRAX-222
Ascending doses of PRAX-222
Escalation of PRAX-222 dose(s)
Fixed-dose(s) of PRAX-222 not to exceed the maximum tolerated dose of PRAX-222
Placebo procedure
Number of participants with treatment-emergent adverse events (Preliminary Safety, Dose Escalation)
The number of participants with treatment-emergent adverse events will be reported by severity and preferred term.
Time frame: Screening (-8 weeks) through up to 92 weeks
Seizure frequency (Confirmatory Phase)
Seizure frequency will be captured by a seizure diary and outcomes will be measured by summing the seizure frequency over a 28-day time period following the 6th dose administration in the confirmatory phase.
Time frame: 36 to 40 weeks
Seizure frequency (Preliminary Safety)
Seizure frequency will be captured by a seizure diary and outcomes will be measured by summing the seizure frequency over a 28-day time period following the 4th dose administration in the preliminary safety phase.
Time frame: 12 to 16 weeks
Seizure frequency (Preliminary Safety)
Seizure frequency will be captured by a seizure diary and outcomes will be measured by summing the seizure frequency over a 28-day time period following each dose administration in the preliminary safety phase.
Time frame: 0 to 4 weeks, 4 to 8 weeks, 8 to 12 weeks
Percent change in seizure frequency (Preliminary Safety)
Seizure frequency will be captured by a seizure diary and outcomes will be measured by summing the seizure frequency over a 28-day time period following each dose administration in the preliminary safety phase. Percent change in seizure frequency will be calculated using a 4-week baseline observation period during Screening as the baseline measure.
Time frame: 0 to 4 weeks, 4 to 8 weeks, 8 to 12 weeks
Number of participants with a treatment response (Preliminary Safety)
Seizure frequency will be captured by a seizure diary and outcomes will be measured by summing the seizure frequency over a 28-day time period following each dose administration in the preliminary safety phase. Percent change in seizure frequency will be calculated using a 4-week baseline observation period during Screening as the baseline measure. Treatment response will be defined as a \>=50% reduction in seizure frequency.
Time frame: 0 to 4 weeks, 4 to 8 weeks, 8 to 12 weeks
Seizure frequency (Dose Escalation Phase)
Seizure frequency will be captured by a seizure diary and outcomes will be measured by summing the seizure frequency over a 28-day time period following the 6th dose administration in the dose escalation phase.
Time frame: 24 to 28 weeks (Group 1), 30 to 34 weeks (Group 2, optional)
Seizure frequency (Dose Escalation Phase)
Seizure frequency will be captured by a seizure diary and outcomes will be measured by summing the seizure frequency over a 28-day time period following each dose administration in the dose escalation phase.
Time frame: 0 to 4 weeks, 4 to 8 weeks, 8 to 12 weeks, 12 to 16 weeks, 18 to 22 weeks, 30 to 34 weeks (Group 1, optional), 36 to 40 weeks (Group 1, optional), 42 to 46 weeks (Group 1, optional), 48 to 52 weeks (Group 1, optional), 54 to 58 weeks (Group 1, optional)
Seizure frequency (Confirmatory Phase)
Seizure frequency will be captured by a seizure diary and outcomes will be measured by summing the seizure frequency over a 28-day time period following each dose administration in the confirmatory phase.
Time frame: 0 to 4 weeks, 6 to 10 weeks, 12 to 16 weeks, 18 to 22 weeks, 24 to 28 weeks
Percent change in seizure frequency (Dose Escalation Phase)
Seizure frequency will be captured by a seizure diary and outcomes will be measured by summing the seizure frequency over a 28-day time period following each dose administration in the dose escalation phase. Percent change in seizure frequency will be calculated using a 4-week baseline observation period during Screening as the baseline measure.
Time frame: 0 to 4 weeks, 4 to 8 weeks, 8 to 12 weeks, 12 to 16 weeks, 18 to 22 weeks, 30 to 34 weeks (optional), 36 to 40 weeks (optional), 42 to 46 weeks (optional), 48 to 52 weeks (optional), 54 to 58 weeks (optional)
Percent change in seizure frequency (Confirmatory Phase)
Seizure frequency will be captured by a seizure diary and outcomes will be measured by summing the seizure frequency over a 28-day time period following each dose administration in the confirmatory phase. Percent change in seizure frequency will be calculated using a 4-week baseline observation period during Screening as the baseline measure.
Time frame: 0 to 4 weeks, 6 to 10 weeks, 12 to 16 weeks, 18 to 22 weeks, 24 to 28 weeks
Number of participants with a treatment response (Dose Escalation Phase)
Seizure frequency will be captured by a seizure diary and outcomes will be measured by summing the seizure frequency over a 28-day time period following each dose administration in the dose escalation phase. Percent change in seizure frequency will be calculated using a 4-week baseline observation period during Screening as the baseline measure. Treatment response will be defined as a \>=50% reduction in seizure frequency.
Time frame: 0 to 4 weeks, 4 to 8 weeks, 8 to 12 weeks, 12 to 16 weeks, 18 to 22 weeks, 30 to 34 weeks (optional), 36 to 40 weeks (optional), 42 to 46 weeks (optional), 48 to 52 weeks (optional), 54 to 58 weeks (optional)
Number of participants with a treatment response (Confirmatory Phase)
Seizure frequency will be captured by a seizure diary and outcomes will be measured by summing the seizure frequency over a 28-day time period following each dose administration in the confirmatory phase. Percent change in seizure frequency will be calculated using a 4-week baseline observation period during Screening as the baseline measure. Treatment response will be defined as a \>=50% reduction in seizure frequency.
Time frame: 0 to 4 weeks, 6 to 10 weeks, 12 to 16 weeks, 18 to 22 weeks, 24 to 28 weeks
Changes in EEG-based outcome measures (Confirmatory Phase)
A vEEG will be performed to record brainwave activity. Changes in mean vEEG measures (including, but not limited to, background frequency, slowing, epileptiform activity, sleep architecture, and seizures) will be calculated
Time frame: Week 2, Week 42
Change from baseline in Clinical Global Impression-Severity (CGI-S) score (Confirmatory Phase)
The CGI-S assesses the clinician's impression of the participant's current epilepsy symptoms. The clinician should use his/her total clinical experience with this patient population and rate the current severity of the participant's symptoms on a 7-point scale from 1 (Normal, not at all affected) to 7 (Among the most extremely affected patients)
Time frame: 6 weeks, 12 weeks, 18 weeks, 24 weeks, 36 weeks, 60 weeks
Change from baseline in Caregiver Global Impression-Severity (CgGI-S) score (Confirmatory Phase)
The CgGI-S assesses the caregiver's impression of the participant's current epilepsy symptoms. The caregiver will rate the current severity of the participant's symptoms on a 7-point scale from 1 (Normal, not at all affected) to 7 (Extremely affected)
Time frame: 6 weeks, 12 weeks, 18 weeks, 24 weeks, 36 weeks, 60 weeks
Clinical Global Impression-Improvement (CGI-I) score (Confirmatory Phase)
The CGI-I assesses the participant's improvement (or worsening). The clinician is required to assess the participant's condition relative to Baseline (Day 1) on a 7-point scale from 1 (Very much improved) to 7 (Very much worse).
Time frame: 6 weeks, 12 weeks, 18 weeks, 24 weeks, 36 weeks, 60 weeks
Caregiver Global Impression-Improvement (CgGI-I) score (Confirmatory Phase)
The CgGI-I assesses the participant's improvement (or worsening). The caregiver is required to assess the participant's condition relative to Baseline (Day 1) on a 7-point scale from 1 (Very much improved) to 7 (Very much worse).
Time frame: 6 weeks, 12 weeks, 18 weeks, 24 weeks, 36 weeks, 60 weeks
Developmental milestones (Confirmatory Phase)
Developmental milestones will be assessed using the Bayley Scales of Infant Development - Fourth Edition (Bayley-4) domain and subtest scores or the Wechsler Preschool and Primary Scales of Intelligence - Fourth Edition (WPPSI-IV). The Bayley-4 is a standardized neurodevelopmental assessment measure used by clinicians to evaluate key domains in early childhood development for individuals between 16 days and 42 months after birth. Each domain includes a variable number of items for assessing development. Each item is scored as a 0, 1, or 2 based on the child's response to the rater's prompt or instruction. Higher scores on the Bayley-4 indicate more advanced development. The WPPSI-IV is a comprehensive test used to assess cognitive function in children from the age of 2 years 6 months to 7 years 7 months. Higher scores on the WPPSI-IV indicate more advanced development.
Time frame: 36 weeks
Quality of life as assessed by Quality of Life Inventory-Disability (Confirmatory Phase)
The QI-Disability is a parent-report measure for children with intellectual disabilities. Parents report on engagement in and enjoyment of activities and behaviors related to health and well-being, feelings and emotions, family and friends, activities and the outdoors, and daily life. 32 items are rated on a 5-point scale from 0 (Never) to 4 (Very often). Higher scores on the QI-Disability indicate more frequent and more enjoyable behavior and activity.
Time frame: 36 weeks
Behavior as assessed by Vineland Adaptive Behavior Scale-3rd edition (Vineland-3; Confirmatory Phase)
The Vineland-3 is a clinician-assessed measure of adaptive behavior in individuals with intellectual disabilities using information obtained via interview of a caregiver or parent. Individuals are assessed on frequency of adaptive behaviors in the following domains: communication, daily living skills, socialization, and motor skills. Each domain has a variable number of items. Each item is scored on a 2 or 3-point scale from 0 (Never) to 2 (Usually). Higher scores indicate more frequent behaviors.
Time frame: 36 weeks
Behavior as assessed by Aberrant Behaviors Checklist-2nd edition (ABC-2; Confirmatory Phase)
The ABC-2 is a clinician-assessed rating scale consisting of 58 items that measure the severity of a range of problem behaviors commonly observed in individuals with intellectual disabilities, including irritability, social withdrawal, stereotypic behavior, hyperactivity, and inappropriate speech. Items are rated on a 4-point scale from 0 (not at all a problem) to 3 (the problem is severe in degree). Higher scores indicate more aberrant behaviors.
Time frame: 36 weeks
Sleep as assessed by Sleep Disturbance Scale for Children (Confirmatory Phase)
The parent-reported Sleep Disturbance Scale for Children (SDSC) is a 26-item scale designed to categorize sleep disorders in children. In addition to an overall score, the instrument provides 5 sub-scores for the following: disorders of initiating and maintaining sleep, sleep breathing disorders, disorders of arousal or sleep-wake transition disorders, disorders of excessive somnolence, and sleep hyperhidrosis. Most items are scored on a 5-point scale from 1 (Never) to 5 (Always). The amount of time spent asleep and the length of time taken to fall asleep is also used in calculating the score. Higher scores on the SDSC indicate more sleep disturbances.
Time frame: 36 weeks
Plan to share: No
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Praxis Precision Medicines